Øvrehus Marius Altern, Rise Langlo Knut Asbjørn, Leh Sabine, Eikrem Øystein, Romundstad Solfrid, Aksnes Håvard, Manner Ingjerd Wangensteen, Aalborg Christian, Solbu Marit D, Gøransson Lasse G, Marti Hans-Peter, Shlipak Michael G, Ix Joachim H, Hallan Stein I
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Nephrology, St. Olavs Hospital, Trondheim University Hospital, P.b. 3250, Trondheim, Torgarden, NO, 7006, Norway.
BMC Nephrol. 2025 Feb 13;26(1):76. doi: 10.1186/s12882-025-04007-4.
Biobanks that hold blood, urine and kidney tissue are key for translational nephrology research but are few and have limited availability. We describe the organization, baseline characteristics, and generalizability of a low-cost national biobank.
Eight Norwegian hospitals participated in this multi-center, prospective cohort study and biobank initiative. Patients referred for routine clinical native kidney biopsies were eligible for inclusion, starting September 2020. Extensive information on medical history and risk factors were collected into an encrypted on-line database by the treating nephrologist. A comprehensive standardized panel of blood and urine tests were analyzed in the clinical routine and registered along with the full histology report. Extra urine and blood samples were collected, aliquoted and prepared locally within two hours, frozen at -80 C, and later sent to a central government-funded biorepository together with remaining kidney biopsy material.
By September 2023, a total of 633 patients were included out of 1050 eligible patients. Mean age was 52.6 years (SD 18.7), 384 (61%) were men, and participants displayed a wide spectrum of kidney disease with mean estimated glomerular filtration rate (eGFR) 53 mL/min/1.73m. The most frequent biopsy indications were progressive chronic kidney disease (CKD) of unknown cause, acute kidney disease, and isolated hematuria/proteinuria. The most frequent diagnoses were IgA nephropathy (21%), arterionephrosclerosis (13%), and diabetes nephropathy (9%). Biopsy indications and diagnoses were similar to the spectrum typically seen in Norway and other western countries, and similar population level kidney health measures were demonstrated for Norway, United Kingdom, and USA.
We demonstrate the feasibility of establishing a large national kidney biopsy biobank across a variety of clinical and histopathologic diagnoses. Blood and urine were stored, accompanied by kidney tissue, at a moderate cost due to a combination of a dedicated nephrology workforce, routine clinical care, and established biobank facilities.
保存血液、尿液和肾脏组织的生物样本库是转化肾脏病学研究的关键,但数量稀少且可用性有限。我们描述了一个低成本国家生物样本库的组织架构、基线特征和普遍性。
八家挪威医院参与了这项多中心前瞻性队列研究和生物样本库计划。自2020年9月起,因常规临床进行肾活检而转诊的患者符合纳入条件。治疗肾病专家将详细的病史和风险因素信息收集到一个加密的在线数据库中。在临床常规操作中对一套全面的标准化血液和尿液检测项目进行分析,并与完整的组织学报告一起记录。额外的尿液和血液样本在两小时内在当地收集、分装并制备,于-80°C冷冻,随后与剩余的肾活检材料一起送往中央政府资助的生物样本库。
截至2023年9月,1050名符合条件的患者中有633名被纳入。平均年龄为52.6岁(标准差18.7),384名(61%)为男性,参与者呈现出广泛的肾脏疾病类型,平均估计肾小球滤过率(eGFR)为53 mL/min/1.73m²。最常见的活检指征是病因不明的进行性慢性肾脏病(CKD)、急性肾脏病以及孤立性血尿/蛋白尿。最常见的诊断是IgA肾病(21%)、动脉性肾硬化(13%)和糖尿病肾病(9%)。活检指征和诊断与挪威及其他西方国家通常所见的情况相似,并且挪威、英国和美国在人群层面的肾脏健康指标也相似。
我们证明了建立一个涵盖各种临床和组织病理学诊断的大型国家肾活检生物样本库的可行性。由于有专门的肾病工作团队、常规临床护理以及已建立的生物样本库设施,血液、尿液与肾脏组织得以以适度成本保存。